Potential COVID-19 papain-like protease PL pro inhibitors: repurposing FDA-approved drugs
Citations Over TimeTop 10% of 2020 papers
Abstract
Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PLpro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19.
Related Papers
- → The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions(2018)113 cited
- → A data-driven methodology towards evaluating the potential of drug repurposing hypotheses(2021)29 cited
- → Treatment Repurposing using Literature-related Discovery(2019)4 cited
- → Drug Repurposing and Multi-Target Therapies(2018)2 cited
- → Faculty Opinions recommendation of Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.(2021)